The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely ...
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that ...
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...
Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability ...
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on ...
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results